AKT1 and acute lymphoblastic leukemia: GRh2 exhibits immune regulation and anti-tumor effects in T-cell acute lymphoblastic leukemia (T-ALL) by blocking the Phosphatidylinositol 3-kinase/ Mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway, enhancing immunity in the spleen, promoting intestinal homeostasis, and altering the composition of gut microbiota, indicating that it may have the potential for the prevention and treatment of T-ALL.39